Merck completes $5.8 billion acquisition of Terns Pharma

At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia

CARBOGEN AMCIS Shanghai site clears unannounced NMPA GMP inspection

Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China

Experts call for easing access to 2mg and 4mg nicotine replacement therapies

With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical

China poised to launch world’s first CAR-T therapy for gastric cancer

As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies

ADMA Biologics wins FDA nod to expand ASCENIV use in young children

Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum

The standout story remains Wegovy, particularly its new oral formulation

Lilly’s Omvoh shows rare long-term remission milestone in ulcerative colitis

Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints

The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients

Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility

The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026

Pfizer powers ahead in 2026 with strong Q1 results as pipeline momentum builds

The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook